These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 9374093)

  • 61. A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer: preliminary results. Taxol Investigational Trials Group, Australia/New Zealand.
    Bishop JF; Dewar J; Toner G; Tattersall MH; Olver I; Ackland S; Kennedy I; Goldstein D; Gurney H; Walpole E; Levi J; Stephenson J
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-5-S17-9. PubMed ID: 9374084
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial.
    Gogas H; Dafni U; Karina M; Papadimitriou C; Batistatou A; Bobos M; Kalofonos HP; Eleftheraki AG; Timotheadou E; Bafaloukos D; Christodoulou C; Markopoulos C; Briasoulis E; Papakostas P; Samantas E; Kosmidis P; Stathopoulos GP; Karanikiotis C; Pectasides D; Dimopoulos MA; Fountzilas G
    Breast Cancer Res Treat; 2012 Apr; 132(2):609-19. PubMed ID: 22187126
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial.
    Conte PF; Guarneri V; Bruzzi P; Prochilo T; Salvadori B; Bolognesi A; Aldrighetti D; Venturini M; Rosso R; Mammoliti S; Carnino F; Giannessi P; Costantini M; Moyano A; Baldini E;
    Cancer; 2004 Aug; 101(4):704-12. PubMed ID: 15305399
    [TBL] [Abstract][Full Text] [Related]  

  • 64. High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study.
    Cottu PH; Extra JM; Espie M; Marolleau JP; de Roquancourt A; Makke J; Miclea JM; Laurence V; Mayeur D; Lerebours F; Cuvier C; Marty M
    Br J Cancer; 2001 Nov; 85(9):1240-6. PubMed ID: 11720455
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pathological and clinical response of a primary chemotherapy regimen combining vinorelbine, epirubicin, and paclitaxel as neoadjuvant treatment in patients with operable breast cancer.
    Abrial C; Van Praagh I; Delva R; Leduc B; Fleury J; Gamelin E; Sillet-Bach I; Penault-Llorca F; Amat S; Chollet P
    Oncologist; 2005 Apr; 10(4):242-9. PubMed ID: 15821244
    [TBL] [Abstract][Full Text] [Related]  

  • 66. High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Center trial.
    Vermorken JB; ten Bokkel Huinink WW; Mandjes IA; Postma TJ; Huizing MT; Heimans JJ; Beijnen JH; Bierhorst F; Winograd B; Pinedo HM
    Semin Oncol; 1995 Aug; 22(4 Suppl 8):16-22. PubMed ID: 7543699
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A phase I dose finding study of a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel in patients with advanced esophageal cancer.
    van der Gaast A; Kok TC; Vos R; Kerkhofs L; Splinter TA
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-82-S19-85. PubMed ID: 9427273
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Phase I study of Taxol, doxorubicin, plus granulocyte-colony stimulating factor in patients with metastatic breast cancer.
    Fisherman JS; McCabe M; Noone M; Ognibene FP; Goldspiel B; Venzon DJ; Cowan KH; O'Shaughnessy JA
    J Natl Cancer Inst Monogr; 1993; (15):189-94. PubMed ID: 7517154
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Chemotherapy for relapsed head and neck cancer: paclitaxel, cisplatin, and 5-fluorouracil in chemotherapy-naive patients. A dose-finding study.
    Benasso M; Numico G; Rosso R; Merlano M; Ricci I; Gentile A
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-46-S19-50. PubMed ID: 9427266
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Acute hematologic feasibility of G-CSF supported dose-escalated FEC therapy as adjuvant treatment after breast cancer surgery.
    Ottosson S; Magnusson K; Hultborn R
    Anticancer Res; 1999; 19(5C):4429-34. PubMed ID: 10650787
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
    Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
    Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Eastern Cooperative Oncology Group studies of paclitaxel and doxorubicin in advanced breast cancer.
    Sledge GW; Robert N; Sparano JA; Cogleigh M; Goldstein LJ; Neuberg D; Rowinsky E; Baughman C; McCaskill-Stevens W
    Semin Oncol; 1995 Jun; 22(3 Suppl 6):105-8. PubMed ID: 7597425
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Paclitaxel/5-fluorouracil/leucovorin in metastatic breast cancer: a Vanderbilt Cancer Center phase II trial.
    Nicholson B; Paul D; Shyr Y; Garrett M; Hande KR; Johnson DH
    Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-20-S11-23. PubMed ID: 9314294
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Dose-dense epirubicin and paclitaxel with G-CSF: a study of decreasing intervals in metastatic breast cancer.
    Lalisang RI; Voest EE; Wils JA; Nortier JW; Erdkamp FL; Hillen HF; Wals J; Schouten HC; Blijham GH
    Br J Cancer; 2000 Jun; 82(12):1914-9. PubMed ID: 10864197
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Treatment of advanced and relapsing breast cancer with a combination of paclitaxel and mitoxantrone. South-Central Hellenic Oncology Group.
    Panagos GE
    Semin Oncol; 1997 Feb; 24(1 Suppl 3):S17-21. PubMed ID: 9071335
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer.
    Elias AD; Richardson P; Avigan D; Ibrahim J; Joyce R; Demetri G; Levine J; Warren D; Arthur T; Reich E; Wheele C; Frei E; Ayash L
    Bone Marrow Transplant; 2001 Feb; 27(3):269-78. PubMed ID: 11277174
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Doxorubicin plus paclitaxel in advanced breast cancer.
    Dombernowsky P; Boesgaard M; Andersen E; Jensen BV
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-15-S17-8. PubMed ID: 9374086
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Tolerance of paclitaxel 3-hour infusion with and without granulocyte colony-stimulating factor on a biweekly schedule.
    Garcia AA; Parimoo D; Dimery I; Rogers M; Jeffers S; Muggia FM
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-62-S19-66. PubMed ID: 9427269
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer: BRE-26, a phase II trial.
    Johnson DH; Paul D; Hande KR
    Semin Oncol; 1997 Feb; 24(1 Suppl 3):S22-5. PubMed ID: 9071336
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: a preliminary report.
    Hussain M; Salwen W; Kucuk O; Ensley J
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-43-S19-45. PubMed ID: 9427265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.